pyridazine has been researched along with warfarin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besada, P; Borges, F; Costas-Lago, MC; Rodríguez-Enríquez, F; Terán, C; Uriarte, E; Vilar, S; Viña, D | 1 |
| Alonso-Pena, M; Besada, P; Costas-Lago, MC; Fontenla, JÁ; Moro, S; Quezada, E; Rodríguez-Enríquez, F; Sturlese, M; Terán, C; Torres-Terán, I; Viña, D | 1 |
2 other study(ies) available for pyridazine and warfarin
| Article | Year |
|---|---|
Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
Topics: Coumarins; Dose-Response Relationship, Drug; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridazines; Structure-Activity Relationship | 2017 |
Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.
Topics: Animals; Coumarins; Dose-Response Relationship, Drug; Humans; Injections, Intraperitoneal; Male; Mice; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pyridazines; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |